influenza hemagglutinin (307-319)

a synthetic peptide derived from hemagglutinin of a human influenza virus strain; amino acid sequence given in first source
Also Known As:
HA(307-319); HA307-319; hemagglutinin (307-319)
Networked: 8 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results


1. Beyrath, Julien: 1 article (07/2011)
2. Fournel, Sylvie: 1 article (07/2011)
3. Schuber, Francis: 1 article (07/2011)
4. Brayé, Mélanie: 1 article (07/2011)
5. Heurtault, Béatrice: 1 article (07/2011)
6. Frisch, Benoît: 1 article (07/2011)
7. Thomann, Jean-Sébastien: 1 article (07/2011)
8. Weidner, Steffen: 1 article (07/2011)
9. Wels, W S: 1 article (04/2005)
10. Frisch, B: 1 article (04/2005)

Related Diseases

1. Human Influenza (Influenza)
05/01/1993 - "In this study, we have examined the lymphocyte proliferative response (LPR) for HA307-319, a synthetic peptide, derived from hemagglutinin of a human influenza virus A strain, and the binding capacities of several DR and DQ molecules, which are frequently expressed in Japanese, with HA307-319. "
04/25/2005 - "We have designed novel multivalent liposomal constructs that co-deliver the p63-71 cytotoxic T Lymphocyte epitope derived from human ErbB2 (HER2), and HA307-319, a T-helper (Th) epitope derived from influenza haemagglutinin. "
05/15/1993 - "Several analogues of the influenza hemagglutinin (H3) peptide HA307-319 were shown to block recognition of the native HA307-319 peptide by a DR1-restricted T cell clone at concentrations 1,000- to 10,000-fold less than required to competitively inhibit HA307-319 binding to DR1. "
03/01/2005 - "This strategy was successfully applied to the reported haemaglutinin influenza peptide HA(307-319), and then extended to three candidate HLA-DR-restricted p53 peptides predicted by the evidence-based algorithm SYFPEITHI to bind to HLA-DRbeta1*0101 (HLA-DR1) and HLA-DRbeta1*0401 (HLA-DR4) molecules. "
11/01/1999 - "To define the relative contributions of HLA and peptide contacts with TCR complementarity-determining region (CDR) 3 residues in T cell recognition, systematic mutagenesis and domain swapping was conducted on two highly similar TCRs that both respond to the influenza hemagglutinin (HA) peptide, HA307-319, but with different HLA restrictions. "
2. Neoplasms (Cancer)

Related Drugs and Biologics

1. Hemagglutinins (Hemagglutinin)
2. HLA-DR Antigens (HLA-DR)
3. Complementarity Determining Regions (Complementarity Determining Region)
4. Peptides
5. Liposomes (Liposome)
6. Ligands
7. Insulin (Novolin)
8. Deoxycytidine (CDR)
9. Carbon Monoxide
10. Antigens